UCLA and Leica Biosystems to collaborate in digital pathology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The UCLA Department of Pathology and Laboratory Medicine and Leica Biosystems will collaborate in digital pathology.

Product testing will be conducted with UCLA to validate digital pathology in a high-volume setting. This joint effort builds upon the existing relationship between UCLA and Leica Biosystems that was established in 2011.

The pathology team at UCLA will be working with Leica Biosystems Aperio ePathology and will test and provide quantitative feedback on current and next-generation products from bench research to full clinical adoption.

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login